Lp(a) is a modified form of LDL. It consists of an LDL-like particle with a distinctive apolipoprotein(a) attached via a disulfide bond to ApoB-100. This structural modification makes Lp(a) more atherogenic than standard LDL: it has increased affinity for the arterial wall, promotes thrombosis by interfering with plasminogen (the body's clot-dissolving system), and drives inflammation within developing plaques. The result is a cardiovascular risk factor that operates through multiple pathways simultaneously — particle deposition, clot formation, and plaque inflammation.
Clinical bottom line: you can have perfectly controlled cholesterol, blood pressure, and blood sugar while carrying an Lp(a) level that triples your cardiovascular risk. You cannot know unless you test. And once you know, the clinical response changes significantly.
What is Lp(a) and why is it genetically determined?
Lp(a) levels are approximately 70–90% genetically determined, primarily by variations in the LPA gene that codes for apolipoprotein(a). Unlike LDL cholesterol — which responds meaningfully to diet, exercise, and medication — Lp(a) is largely fixed at birth and remains relatively stable throughout adult life. Statins, which effectively lower LDL-C, do not reduce Lp(a) and in some cases slightly raise it.
This genetic independence is what makes Lp(a) both distinctive and important. It means that a person with elevated Lp(a) cannot 'lifestyle their way' to a normal result in the way they might address elevated triglycerides or fasting insulin. The appropriate clinical response is not denial or passive monitoring — it is knowing the level, understanding what it means for lifetime risk, managing all modifiable cardiovascular risk factors with greater precision, and, in cases of significant elevation, exploring pharmacological options as they become available.
What are high and normal Lp(a) levels in the UK?
Lp(a) is measured in two units — nmol/L or mg/dL — and different laboratories use different standards. It is important to know which unit your result uses when interpreting it:
- Optimal: below 75 nmol/L (approximately below 30 mg/dL) — associated with average or below-average Lp(a)-related cardiovascular risk.
- Borderline elevated: 75–125 nmol/L (approximately 30–50 mg/dL) — modest additional risk; increased vigilance regarding other cardiovascular risk factors recommended.
- Elevated: above 125 nmol/L (approximately 50 mg/dL) — significant additional cardiovascular risk; active management of all modifiable risk factors is strongly indicated.
- Severely elevated: above 200 nmol/L — places the individual in a high-risk category equivalent to heterozygous familial hypercholesterolaemia; specialist cardiovascular review is appropriate.
The 2022 European Atherosclerosis Society consensus statement recommends at least one Lp(a) measurement during adult life for all individuals. Major guidelines now include Lp(a) as a cardiovascular risk-enhancing factor that should modify treatment decisions. Despite this, it remains routinely absent from NHS lipid panels in most settings.
Why elevated Lp(a) matters even when everything else looks fine
The most clinically significant aspect of Lp(a) is its independence from other risk factors. Elevated Lp(a) adds risk on top of — not instead of — the contribution from LDL-C, blood pressure, smoking, insulin resistance, and family history. This means:
- A person with otherwise well-managed cardiovascular risk can still face substantially elevated lifetime risk if Lp(a) is significantly elevated.
- Elevated Lp(a) approximately doubles or triples cardiovascular risk at a population level, with risk scaling with Lp(a) level.
- Lp(a) is strongly associated with premature ASCVD — heart attack and stroke before age 55 in men and 65 in women — and with aortic valve stenosis.
- If someone in your immediate family had a heart attack 'young' without obvious conventional risk factors, Lp(a) should be tested in all first-degree relatives.
Knowing an elevated Lp(a) changes clinical management in several ways. It strengthens the case for earlier and more aggressive LDL-C lowering, since reducing ApoB burden reduces the atherogenic insult that Lp(a) amplifies. It influences the threshold for aspirin therapy, statin initiation, and — when evidence-based options become available — Lp(a)-specific therapies. It also shapes the case for coronary artery calcium scoring as a further risk stratification tool.
Why doesn't the NHS routinely test Lp(a)?
NHS cardiovascular risk assessment uses the QRISK3 algorithm, which incorporates age, sex, family history, blood pressure, cholesterol ratio, deprivation, and several conditions. Lp(a) is not a current QRISK3 input, partly because it is not yet captured in primary care records and partly because there have been no licenced Lp(a)-specific treatments until recently.
The clinical rationale for Lp(a) testing has strengthened considerably in recent years. NICE guidance now recognises Lp(a) as a cardiovascular risk enhancer in specific clinical contexts, and the NHS Long Term Plan includes commitments to familial hypercholesterolaemia cascades where Lp(a) is part of the risk picture. But universal population screening is not yet standard practice, meaning most people with elevated Lp(a) remain undiagnosed until a cardiovascular event prompts investigation.
Who should get a private Lp(a) test in the UK?
- Anyone with a family history of early cardiovascular disease — a parent, sibling, or first-degree relative who had a heart attack or stroke before age 60.
- Anyone with a personal or family history of familial hypercholesterolaemia (FH) — elevated Lp(a) is particularly common in FH patients.
- Anyone who has had a cardiovascular event that seemed unexplained or occurred at an unusually young age.
- Anyone with high cardiovascular risk on conventional markers who wants to understand whether additional genetic risk is present.
- Anyone undergoing a longevity or comprehensive health review — knowing your Lp(a) once is clinically valuable for lifetime risk planning.
- Anyone with aortic valve disease or calcification — Lp(a) is an independent driver of aortic stenosis.
What can be done about elevated Lp(a)?
While Lp(a) itself is not currently modifiable by most available interventions, an elevated result is far from clinically meaningless. The evidence-based response includes:
- Aggressive LDL-C and ApoB reduction: lowering the overall atherogenic particle burden reduces the amplified risk that elevated Lp(a) creates. ApoB targets should be lower in the context of high Lp(a).
- Aspirin consideration: Lp(a) promotes thrombosis; in high Lp(a) with additional risk factors, low-dose aspirin may be considered as part of an individualised cardiovascular risk discussion.
- PCSK9 inhibitor therapy: in eligible patients, PCSK9 inhibitors modestly reduce Lp(a) (by approximately 20–30%) in addition to their substantial LDL-C lowering effect.
- Emerging therapies: RNA-targeted therapies (including siRNA and antisense oligonucleotides targeting LPA) are in late-stage clinical trials and represent a near-future Lp(a)-specific option. Phase III trial data is compelling.
- Lifestyle optimisation for all other modifiable factors: blood pressure, insulin resistance, smoking cessation, ApoB, and inflammatory markers all need to be at their best to offset the fixed risk Lp(a) adds.
How Lp(a) is included in Veridian's Longevity Panel
Lp(a) is a standard component of Veridian's Longevity Panel (£795), which includes 150+ markers covering cardiovascular risk, metabolic function, organ health, hormones, inflammation, and a biological age estimate. Lp(a) is interpreted alongside ApoB, fasting insulin, triglycerides, HbA1c, and inflammatory markers — the full cardiovascular context that makes a single Lp(a) number clinically meaningful.
Every Longevity Panel result is accompanied by a GP-written report that explains what your Lp(a) level means for your lifetime cardiovascular risk, how it should influence your approach to ApoB management, and whether any specialist review or further investigation is indicated.
- Lp(a) included in Longevity Panel (£795).
- Interpreted alongside ApoB, fasting insulin, and full cardiovascular risk picture.
- Nationally accredited UK laboratory processing.
- GP-written results report with personalised action plan.
Related reading: Lp(a), ApoB, and triglycerides — the triple cardiovascular threat · ApoB vs LDL — why particle count matters more than cholesterol mass · Fasting insulin and early metabolic dysfunction
Related Tests